Barclays’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-536,999
| Closed | -$2.26M | – | 5353 |
|
|
2023
Q1 | $2.26M | Sell |
536,999
-221,362
| -29% | -$1.15M | ﹤0.01% | 2102 |
|
|
2022
Q4 | $4.56M | Buy |
758,361
+79,748
| +12% | +$435K | ﹤0.01% | 1697 |
|
|
2022
Q3 | $3.95M | Buy |
678,613
+673,949
| +14,450% | +$4.2M | ﹤0.01% | 1308 |
|
|
2022
Q2 | $28K | Buy |
4,664
+4,648
| +29,050% | +$23.8K | ﹤0.01% | 4280 |
|
|
2022
Q1 | $0 | Sell |
16
-500
| -97% | -$1.49K | ﹤0.01% | 5861 |
|
|
2021
Q4 | $1K | Sell |
516
-25,592
| -98% | -$62.6K | ﹤0.01% | 4086 |
|
|
2021
Q3 | $77K | Buy |
26,108
+20,503
| +366% | +$55.8K | ﹤0.01% | 4001 |
|
|
2021
Q2 | $14K | Sell |
5,605
-59,349
| -91% | -$142K | ﹤0.01% | 4573 |
|
|
2021
Q1 | $190K | Buy |
64,954
+64,437
| +12,464% | +$210K | ﹤0.01% | 3723 |
|
|
2020
Q4 | $2K | Hold |
517
| – | – | ﹤0.01% | 4818 |
|
|
2020
Q3 | $1K | Sell |
517
-880
| -63% | -$1.12K | ﹤0.01% | 5162 |
|
|
2020
Q2 | $2K | Buy |
1,397
+880
| +170% | +$929 | ﹤0.01% | 5463 |
|
|
2020
Q1 | $0 | Hold |
517
| – | – | ﹤0.01% | 6770 |
|
|
2019
Q4 | $1K | Hold |
517
| – | – | ﹤0.01% | 6299 |
|
|
2019
Q3 | $0 | Sell |
517
-490
| -49% | -$374 | ﹤0.01% | 7508 |
|
|
2019
Q2 | $0 | Sell |
1,007
-13,948
| -93% | -$12.9K | ﹤0.01% | 7585 |
|
|
2019
Q1 | $15K | Buy |
14,955
+14,438
| +2,793% | +$15.2K | ﹤0.01% | 6458 |
|
|
2018
Q4 | $0 | Sell |
517
-23,247
| -98% | -$38.2K | ﹤0.01% | 7789 |
|
|
2018
Q3 | $51K | Sell |
23,764
-14,906
| -39% | -$36.9K | ﹤0.01% | 6079 |
|
|
2018
Q2 | $193K | Sell |
38,670
-10,654
| -22% | -$46.6K | ﹤0.01% | 4757 |
|
|
2018
Q1 | $192K | Buy |
49,324
+48,802
| +9,349% | +$172K | ﹤0.01% | 4864 |
|
|
2017
Q4 | $1K | Hold |
522
| – | – | ﹤0.01% | 6894 |
|
|
2017
Q3 | $2K | Hold |
522
| – | – | ﹤0.01% | 6725 |
|
|
2017
Q2 | $2K | Hold |
522
| – | – | ﹤0.01% | 6478 |
|
|
2017
Q1 | $2K | Sell |
522
-30
| -5% | -$138 | ﹤0.01% | 6531 |
|
|
2016
Q4 | $2K | Buy |
552
+30
| +6% | +$124 | ﹤0.01% | 6428 |
|
|
2016
Q3 | $2K | Sell |
522
-2,759
| -84% | -$10K | ﹤0.01% | 6347 |
|
|
2016
Q2 | $11K | Buy |
3,281
+2,759
| +529% | +$12.7K | ﹤0.01% | 5521 |
|
|
2016
Q1 | $0 | Sell |
522
-8,245
| -94% | -$65.9K | ﹤0.01% | 6852 |
|
|
2015
Q4 | $88K | Sell |
8,767
-10,151
| -54% | -$136K | ﹤0.01% | 4487 |
|
|
2015
Q3 | $189K | Buy |
18,918
+17,635
| +1,375% | +$305K | ﹤0.01% | 4185 |
|
|
2015
Q2 | $14K | Sell |
1,283
-171
| -12% | -$3.3K | ﹤0.01% | 5924 |
|
|
2015
Q1 | $15K | Sell |
1,454
-21,532
| -94% | -$485K | ﹤0.01% | 6011 |
|
|
2014
Q4 | $459K | Buy |
22,986
+508
| +2% | +$11.7K | ﹤0.01% | 3935 |
|
|
2014
Q3 | $449K | Buy |
22,478
+15,752
| +234% | +$410K | ﹤0.01% | 4037 |
|
|
2014
Q2 | $134K | Sell |
6,726
-1,545
| -19% | -$46.4K | ﹤0.01% | 5194 |
|
|
2014
Q1 | $247K | Sell |
8,271
-10,526
| -56% | -$360K | ﹤0.01% | 4591 |
|
|
2013
Q4 | $188K | Buy |
18,797
+2,979
| +19% | +$54.2K | ﹤0.01% | 5068 |
|
|
2013
Q3 | $158K | Buy |
15,818
+15,225
| +2,567% | +$176K | ﹤0.01% | 5247 |
|
|
2013
Q2 | $6K | Buy |
+593
| New | +$6.95K | ﹤0.01% | 7339 |
|
Other funds holding CTIC
Barclays's CTIC Position: Q2 2023 in Review
Barclays sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 536,999 shares — an estimated $2.26M sold.
Barclays first reported a position in CTIC in Q2 2013 and held it in 40 quarters. The position peaked at $4.56M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Barclays reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Barclays sold 536,999 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.26M.
- Barclays first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 40 quarters.
- Barclays's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.56M in Q4 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.